Vertex Opts for Avalon to Progress VX-944
By Business Review Editor
Pharma Deals Review: Vol 2005 Issue 58 (Table of Contents)
Published: 1 Apr-2005
DOI: 10.3833/pdr.v2005.i58.694 ISSN: 1756-7874
Section: Features
Fulltext:
Abstract
Vertex has partnered its oncology agent VX-944 in a deal worth up to US$73 M...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018